The Committee for Medicinal Products for Human Use recommends marketing approval for Merck's Keytruda for treating two types ...

Besides stomach cancer, the FDA also raised a similar concern for PD-1 drugs in first-line esophageal squamous cell carcinoma ...

The EMA CHMP has recommended approval of MSD’s KEYTRUDA for two gynaecological cancers: endometrial and cervical.

An FDA advisory panel on Bristol Myers Squibb Opdivo and Merck Keytruda will examine if PD-L1 tumor expression should limit ...

Keytruda (pembrolizumab) is an immunotherapy drug used to treat many types of cancer. Your doctor will use imaging, blood tests, and other laboratory tests to monitor whether the drug is working.

Rahway: Merck, known as MSD outside of the United States and Canada, has announced that the European Medicines Agency's ...

When given after organ-removal surgery, Keytruda brings patients battling advanced bladder cancers more time cance ...

The approval for the KEYTRUDA regimen is supported by results from the Phase II/III IND.227/KEYNOTE-483 trial.

In 2021, the FDA blasted Merck for using a premature endpoint to pursue a Keytruda approval in early-stage triple-negative ...

Merck & Co. said a European Medicines Agency panel recommended expanded approval of the drugmaker's blockbuster cancer treatment Keytruda in two types of gynecologic cancers.

EU CHMP recommends approval of Merck’s Keytruda regimens as treatment for patients with two types of gynaecologic cancers ...

Keytruda plus chemo has been approved for unresectable advanced or metastatic malignant pleural mesothelioma based on ...